Clinical Trials Logo

Clinical Trial Summary

This research protocol is comparing the effectiveness of surgical excision to the "wait and see" approach for the management of oral leukoplakia and erythroleukoplakia in prevention of oral squamous cell carcinoma onset.

Clinical Trial Description

Different treatments have been proposed for the management of oral leukoplakia (OL) in order to prevent oral squamous cell carcinoma onset. However, there is still no consensus on the most effective approach for the patients affected by such oral potentially malignant disorders. Surgery is often performed, but there is no randomized clinical trial which demonstrates its real effectiveness in preventing oral cancer onset. A recent RCT compared surgical treatment with "wait and see approach" care in patients with nondysplastic OL, assuming that regular clinical follow-up could be considered a reliable standard of care among patients with nondysplastic oral leukoplakias. The purpose of this study is to evaluate effectiveness of surgical excision in treating OL and or prolonging the onset of potential oral squamous cell carcinoma. This study will be the first RCT comparing the effectiveness of surgery to "wait and see approach" in the management of both dysplastic and nondysplastic oral leukoplakias. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04858100
Study type Interventional
Source University of Milan
Contact Giovanni Lodi, PhD, DMD
Phone 00390250319021
Email [email protected]
Status Recruiting
Phase N/A
Start date February 25, 2021
Completion date March 1, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03239834 - Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
Not yet recruiting NCT03939364 - This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions Phase 1
Completed NCT00299195 - A Randomized Study of Sulindac in Oral Premalignant Lesions N/A
Recruiting NCT03692325 - Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Phase 2